When women are well, the effect does not stop with them.
Impact is clinical, but it is also social, economic and industrial. We are building toward all four—and separating what we have done from what we still intend to prove.
We measure progress from the body outward: relief, dignity and earlier care for one person; time and confidence returned to a household; better tools for a clinician; stronger choices for a health system.

Her body
Less pain, earlier visibility, safer recovery and more agency.

Her days
More freedom to study, work, move, sleep and plan.

Her people
Less avoidable caregiving burden and fewer lives reorganised around untreated morbidity.

Her care team
Tools designed for the workflow, not simply dropped into it.

Her health system
Earlier action, stronger local capability and less dependence on distant supply.
Progress without theatre.
programmes spanning market entry, clinical validation, prototyping, formulation research and early feasibility.
East African countries whose women, clinicians and health settings have informed the work.
shared development discipline: listen, engineer, test, disclose the stage, repeat.
Different programmes. Different evidence thresholds.
We do not use the maturity of one programme to overstate another. Each has its own next milestone.
World-class products. Local capability. Care that reaches sooner.
Our intended impact is ambitious. Our claims will remain disciplined. Product-specific outcomes will be published only when the relevant bench, safety, usability and clinical evidence supports them.
Fund or study the next milestone




